New hope for kids with tough cancers: elimusertib trial launches
NCT ID NCT05071209
First seen Jan 28, 2026 · Last updated Jun 19, 2026 · Updated 15 times
Summary
This study tests a drug called elimusertib in children and young adults (ages 1 to 30) whose solid tumors have returned or not responded to treatment. The drug works by blocking an enzyme that cancer cells need to grow. The trial aims to find the safest dose and see if the drug can shrink tumors. It is a Phase 1/2 study with 31 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77030, United States
-
C S Mott Children's Hospital
Ann Arbor, Michigan, 48109, United States
-
Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, H3T 1C5, Canada
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Alabama
Birmingham, Alabama, 35233, United States
-
Children's Hospital of Orange County
Orange, California, 92868, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, 15224, United States
-
Children's Mercy Hospitals and Clinics
Kansas City, Missouri, 64108, United States
-
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Cook Children's Medical Center
Fort Worth, Texas, 76104, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Johns Hopkins All Children's Hospital
St. Petersburg, Florida, 33701, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Lurie Children's Hospital-Chicago
Chicago, Illinois, 60611, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Riley Hospital for Children
Indianapolis, Indiana, 46202, United States
-
Saint Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
UCSF Medical Center-Mission Bay
San Francisco, California, 94158, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390, United States
-
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Elimusertib (a drug that blocks an enzyme called ATR, which may help stop cancer cell growth)
What this could lead to
If it works, this could provide a new treatment option for children and young adults with hard-to-treat solid tumors that have come back or not responded to standard therapy.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 31 participants, so the results may not apply to everyone. The drug may cause side effects or not shrink tumors as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.